The Cutting Edge of Medical Technology Content, Community & Collaboration
Drug companies can use genomics to create targeted drugs like imatinib (Gleevec) and trastuzumab (Herceptin.) Physicians can then use the results of genomic studies to guide prescribing. As discussed in prior posts, a person with Philadelphia chromosome-positive (i.e., having the BCR-ABL translocation with its aberrant tyrosine kinase) chronic myelocytic leukemia will likely respond to Gleevec. And a woman whose breast cancer shows high levels of the Her2neu receptor will likely respond to…
ContinueAdded by Stephen C Schimpff on June 3, 2011 at 11:33am — No Comments
© 2024 Created by CC-Conrad Clyburn-MedForeSight. Powered by